Background {#Sec1}
==========

Gastric cancer is the second most common cause of cancer-related death worldwide \[[@CR1]\]. The incidence of gastric carcinoma varies significantly from one part of the world to another and it is particularly common in Eastern Asia, especially in China \[[@CR2]\]. Amplification, overexpression or both, of human epidermal growth factor receptor-2 (HER2, also known as ERBB2), a transmembrane receptor tyrosine kinase, is present in around 6.1--23.0% of gastric cancers \[[@CR3]--[@CR5]\]. In breast cancer, amplification and overexpression of the HER2 gene are associated with poor outcomes, higher mortality, higher recurrence and metastasis \[[@CR6]--[@CR8]\]. However, the prognostic value of HER2 status in gastric cancer remains controversial. Some studies showed that HER2-positive patients had a favorable survival \[[@CR9]--[@CR11]\], while other studies revealed no relationship between HER2 status and survival \[[@CR4], [@CR12]--[@CR14]\]. The majority of the publications showed that a HER2-postive status, measured by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), was associated with poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph node metastases, disease stage, or distant metastases \[[@CR11], [@CR15], [@CR16]\].

Although the Lauren classification system dates back to 1965, it is still widely accepted and employed by pathologists and physicians today. According to the Lauren classification, gastric adenocarcinomas can be divided into diffuse, intestinal and mixed type \[[@CR17]\]. Cohesive cells that form gland-like structures characterize the intestinal type. For the diffuse type, tumor cells lack cell-to-cell interactions and infiltrate the stroma as single cells or small subgroups, leading to a population of non-cohesive, scattered tumor cells \[[@CR17]\]. The intestinal-type is more frequent in males and in elderly patients, while the diffuse-type occurs more frequently in women and young patients \[[@CR18]\]. Intestinal type patients have better outcomes than patients with diffuse-type tumors \[[@CR8], [@CR19]--[@CR21]\]. However, HER2 positivity is more common in intestinal-type gastric cancer \[[@CR15]\]. The higher rate of HER2 positivity and better survival in the intestinal type is controversial. We hypothesized that the combination of the Lauren classification and HER2 status (L-H status) might be more helpful than either factor alone. In this study, we explored the relationship between Lauren classification and HER2 status; moreover, we also analyzed the prognostic value of L-H status.

Methods {#Sec2}
=======

Patient collection {#Sec3}
------------------

From January 1996 to December 2006, we collected clinical information retrospectively from gastric cancer patients who received treatment in our cancer center. Patients included in the study met the following criteria: (1) histologically confirmed gastric adenocarcinoma patients that underwent gastrectomy; (2) adequate paraffin-embedded tumor tissue sample for pathological and HER2 status analysis; and (3) complete medical records with regular survival follow-up data. Overall survival (OS) data was present. The exclusion criteria were: (1) age \<18 years old; and (2) other malignancy within the last 5 years, except carcinoma in situ of the cervix, or basal cell carcinoma.

All patients were categorized according to the 7^th^ American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) stage.

Lauren classification {#Sec4}
---------------------

Assignment of histological type was based on the Lauren criteria. The intestinal type was described as a tumor with glandular architecture, resembling colonic carcinoma. The diffuse type was described as a tumor composed of solitary or small clusters of cells, and lacking glandular structures. The mixed type was described as the combination of these two features. Two pathologists reviewed the original diagnostic slides to make a diagnosis of Lauren classification.

HER2 evaluation {#Sec5}
---------------

### Immunohistochemistry (IHC) {#Sec6}

For all patients, HER2 expression was detected by IHC. IHC staining was carried out using an anti-HER-2/NEU (4B5) antibody (Ventana Medical Systems, Inc. Tucson, AZ, USA) as the primary antibody against HER2 on a Ventana Benchmark XT automatic staining system, according to the manufacturer's instructions. The amended HER2 IHC scoring system for gastric cancer proposed by Hoffmann et al. was used as the criteria for scoring the stained slides \[[@CR22]\].

### Fluorescence in situ hybridization (FISH) {#Sec7}

*HER2* amplification levels were measured when the result of IHC was 2+. The PathVysion®HER2 DNA Probe kit (LSI®HER2/neu Spectrum Orange™/chromosome 7 centromere probe (CEP) ®17 Spectrum Green) was used to perform FISH analysis, according to the manufacturer's protocol. A positive result from FISH was defined as a HER2:CEP17 ratio ≥2.

Any case with IHC 3+ or IHC2+/FISH + was considered to be HER2-positive, while cases with IHC 0 or IHC 1+ or IHC 2+/FISH − were considered as HER2-negative, according to criteria of the European Medicines Agency.

### L-H status {#Sec8}

We divided the patients into six groups according to their Lauren classification and HER2 status (L-H Status): Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type; Group E, HER2 negative and mixed type; and Group F, HER2 positive and mixed type.

### Statistical analysis {#Sec9}

The Statistical Package of Social Sciences 13.0 software performed all the statistical analyses. A P value \<0.05 was considered statistically significant. The Kaplan-Meier method was used to estimate OS. For patients who remained alive, data were censored at the date of the last contact. Kaplan-Meier analysis with log-rank testing was used for univariate analysis. OS was defined as the duration between the date of diagnosis and the date of last contact. Variables showing a trend for association with survival (P \<0.05) and variables that were known to have prognostic value were selected for submission to a final multivariate Cox proportional hazards model, while variables that were highly associated with others were excluded from the final multivariate model. The chi-square test was used to compare the clinicopathological data.

We compared the -2log likelihood (which was the parameter in the Cox regression) of two different models of multivariate analysis: the smaller the value, the better the model \[[@CR23]\].

### Ethics statement {#Sec10}

All patients signed written informed consent for their information to be used for the study. The independent ethics committees at the Cancer Center of Sun Yat-Sen University approved the study. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

This study was registered in the website of ClinicalTrials.Gov with a number of NCT01927146.

Results {#Sec11}
=======

Patient demographics {#Sec12}
--------------------

The median age of the 838 patients was 59 years (rang: 18 to 86 years); 554 were male and 284 were female. There were 88 stage IV patients at the time of diagnosis who all received gastrectomy to relieve the symptom of obstruction or bleeding. During follow-up, 91 patients developed distant metastasis and 12 patients had local recurrence. Until January 1, 2014, 77 patients had died from gastric cancer.

Lauren classification {#Sec13}
---------------------

There were 51.0% (427/838) of patients with diffuse type and 33.9% (284/838) patients with the intestinal type. The remaining 127 (15.1%) patients belonged to the mixed type.

The relationship between clinicopathological features and Lauren classification is showed in Table [1](#Tab1){ref-type="table"}. Among the patients who were younger than 60 years old, 269 (62.7%) had the diffuse type, while for patients who were older than 59 years old; only 158 (38.6%) patients had the diffuse type. The ratio of males to females was significantly higher in the intestinal-type than that in the diffuse-type (3.2 *vs*. 1.3; P \< 0.001). Patients in stages III and IV had a higher percentage of diffuse type than those in the stages I and II.Table 1**Baseline characteristics**Lauren classification***P*** \# valueHER2 status***P*** \* valueDiffuse(%)Intestinal(%)Mixed(%)Negative(%)Positive(%)Sex\<0.0Male242 (43.7)216 (39.0)96 (17.3)01486 (87.7)68 (12.3)0.176Female185 (64.7)68 (23.9)31 (10.9)258 (90.8)26 (9.2)Age\<0.001\<0.001≤59269 (62.7)104 (24.2)56 (13.1)398 (92.8)31 (7.2)\>59158 (38.6)180 (44.0)71 (17.4)346 (84.6)63 (15.4)Stage\<0.0010.406I68 (47.9)60 (42.3)14 (9.8)131(92.3)11 (7.7)II96 (41.7)102 (44.3)32 (13.9)203 (88.3)27 (11.7)III215 (56.9)95 (25.1)68 (18.0)335 (88.6)43 (11.4)IV48 (54.5)27 (30.7)13 (14.8)75 (85.2)13 (14.8)Degree of differentiation\<0.001\<0.001Well + Moderate0 (0)262 (76.2)82 (23.8)270 (78.5)74 (21.5)Poor + signet ring cell427 (86.4)22 (4.5)45 (9.1)474 (96.0)20 (4.0)Location\<0.001\<0.001Proximal110 (35.9)146 (47.7)50 (16.3)251 (82.0)55 (18.0)Distal276 (59.1)128 (27.4)63 (13.5)436 (93.4)31 (6.6)Total stomach41 (63.1)10 (15.4)14 (21.5)57 (87.7)8 (12.3)Adjuvant chemotherapyYes302 (51.4)192 (32.7)94 (15.9)531 (90.3)57 (9.7)No77 (47.5)65 (40.1)20 (12.4)0.170138 (85.2)24 (14.8)0.063HER2: human epidermal growth factor receptor 2.\#*P* values of Lauren classification in different clinical features. \**P* values of HER 2 status in different clinical features.

HER2 status {#Sec14}
-----------

The percentages of IHC negative, 1+, 2+ and 3+ were 51.2% (429/838), 25.5% (214/838), 15.4% (129/838) and 7.9% (66/838), respectively. For the IHC 2+ patients, 28 patients were diagnosed as FISH positive. Thus, the proportion of patients positive for HER2 was 11.2% (94/838) in the whole group of patients.

Among patients who were older than 60 years, there were more HER2 positive patents than among those younger than 59 years old. Stage IV patients had the highest proportion of HER2 positive (14.8%). The relationship between clinicopathological features and HER2 status is shown in Table [1](#Tab1){ref-type="table"}.

L-H status {#Sec15}
----------

The proportions of HER2 positive patients were 25.4%, 2.1% and 10.2% in the intestinal type, diffuse type and mixed type, respectively (P \< 0.001). The median OS (from the time of diagnosis to the time of last contact) was 34.0 months, 25.3 months, 27.6 months, 19.2 months, 25.9 months and 26.4 months in the six groups of patients (P = 0.053). Considering that the mixed type contained the features of diffuse type and intestinal type, the difference between diffuse and intestinal type could not be fully evaluated in the mixed type. In subsequent analyses we only evaluated the value of L-H classification in the diffuse and intestinal types. The number of patients in these four groups was 212, 72, 418 and nine respectively. The median survival was 34.0 months, 25.3 months, 27.6 months and 19.2 months (P \< 0.001; Figure [1](#Fig1){ref-type="fig"}). For the stage IV patients (including 88 concurrent metastasis and 91 metachronous metastasis patients), if we calculated the survival from the time of metastasis to the time of last contact, the median overall survival was 13.7 months, 10.2 months, 10.8 months and 7.9 months (P = 0.001).Figure 1**The survival difference among different L-H status.**

The relationship between L-H status and clinicopathological features is shown in Table [2](#Tab2){ref-type="table"}. From the table, we could conclude that L-H status was a useful index. Among the four L-H groups, the clinicopathological features were quite different, except for the percentage of adjuvant chemotherapy.Table 2**The relationship between different L-H status and clinical features**Group AGroup BGroup CGroup D***P*** valueSexMale163542356Female49181833\<0.001Age≤5982212646\>59130511543\<0.001StageI4810691II8023932III66302113IV189453\<0.001Degree of differentiationWell + Moderate1936900Poor + signet ring cell1934189\<0.001LocationProximal99451111Distal104242697Total stomach93381\<0.001Adjuvant chemotherapyYes144482975No50157610.505Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type.

Survival analysis {#Sec16}
-----------------

Both univariate and multivariable analyses were used to evaluate factors associated with OS. Factors of TNM stage (P \< 0.001), degree of differentiation (P = 0.015), Lauren classification (P = 0.006), HER2 status (P = 0.033) and L-H status (P = 0.003) were all significantly associated with OS in the univariate analysis.To further explore the prognostic value of HER2, we analyzed the survival difference between HER2 positive and HER2 negative patients in intestinal type and diffuse type, respectively. We found that HER2 positivity was an independent adverse prognostic factor in the intestinal type (P \< 0.001), but not in the diffuse type (P = 0.084; Figure [2](#Fig2){ref-type="fig"}A, B).We then analyzed the prognostic value of HER2 positivity in different stages. HER2 positivity was an independent adverse prognostic factor in stage I and II patients (P \< 0.001), but not in stage III and IV patients (P = 0.125; Figure [2](#Fig2){ref-type="fig"}C, D).Figure 2**Kaplan--Meier curves of HER2-positive and -negative patients for overall survival in (A), intestinal type (B), diffuse type (C), TNM stage I/II and (D) TNM stage III/IV.**

For the multivariable regression analysis, we first set up a model (model A) that included age, gender, degree of differentiation, TNM stage, Lauren classification and HER2 status. Model A showed that age, degree of differentiation, TNM stage and Lauren classification were independent factors for OS (*P* = 0.001, 0.017, \<0.001 and 0.047, respectively, Table [3](#Tab3){ref-type="table"}). HER2 status was not an independent prognostic factor (P = 0.285). The -2log likelihood was 1663.155. We then set up another model (model B), which was identical to the first one except that the Lauren classification and HER2 status were replaced by the L-H status. In model B, TNM stage and L-H status were independent factors for OS (P = 0.028, \<0.001 and 0.006, respectively, Table [3](#Tab3){ref-type="table"}). The -2log likelihood was 1411.610.We also analyzed the prognostic value of L-H status in different stages. L-H status was an independent prognostic factor in both early stage (I and II) patients (P \< 0.001) and advanced stage (III and IV) patients (P = 0.036; Figure [3](#Fig3){ref-type="fig"}A, B).Table 3**The multivariable analysis of overall survival in gastric carcinoma**Model AModel BHazard ratio95% CI***P*** valueHazard ratio95% CI***P*** valueGender1.2080.736-1.9830.4550.9840.566-1.7110.954Age2.3021.383-3.8310.0011.4721.059-2.0470.028Stage3.6042.551-5.091\<0.0013.6102.490-5.233\<0.001Degree of differentiation0.5050.288-0.8860.0170.4240.167-1.0740.070Lauren classfication1.4401.004-2.0660.047------HER2 status0.6690.320-1.3980.285------L-H status------2.2221.259-3.9200.006*Abbreviations*: *CI* confidence interval, *HER2* human epidermal growth factor receptor-2, *L-H status* Lauren classification and HER2 status.Model A includes the factors of Lauren classification and HER2 status; Model B includes the combination factor of L-H status.Figure 3**Kaplan--Meier curves of L-H status for overall survival in (A), TNM stage I/II and (B) TNM stage III/IV.**

Discussion {#Sec17}
==========

The prognostic value of HER2 status in gastric cancer remains controversial. Some studies reported that HER2 positivity was an adverse prognostic factor, while some found that it indicated better survival. Other studies even considered that it had no relationship with survival. Based on the Lauren classification, gastric cancers could be divided into the diffuse type, intestinal type and mixed type. The intestinal type has a better survival than the diffuse type. However, intestinal type patients were more likely to be HER2 than diffuse type patients. In our study, HER2 was not an independent prognostic factor for gastric cancer patients in the multivariate analysis. When we separated the patients into diffuse and intestinal types, we found that HER2 was an independent adverse prognostic factor for the intestinal type. We also analyzed the prognostic value of HER2 positivity in patients at different stages. HER2 positivity was an independent prognostic factor for stage I and II patients, but not in stage III and IV patients. This was different from the result of Kataoka et al. \[[@CR14]\]. They analyzed 213 Japanese gastric cancer patients retrospectively and found that the OS of HER2-negative and -positive patients was not significantly different in the whole group patients. However, in patients with stage III/IV, they found that the OS was worse in HER2-positive patients (P = 0.0149) \[[@CR14]\]. In the 2012 European Society for Medical Oncology (ESMO) conference, a multicenter study conducted by Kurokawa et al. showed that HER2 positivity was an independent prognostic factor in stage I and II patients, but not in stage III and IV patients \[[@CR24]\]. This was consistent with our results. These were all retrospective analyses. Therefore, prospective studies are required to explore the prognostic value of HER2 in early stage gastric cancer patients.

Based on the analysis above, we hypothesized that when we discussed the prognostic value of HER2 positive, there were other factors that should be into consideration, such as the TNM stage and the Lauren classification.

HER2 positivity was much more common in the proximal, intestinal type and stage IV gastric cancer patients. Male, older patients and proximal gastric cancer patients had a higher percentage of intestinal type. These basic clinicopathological features were all consistent with previous studies \[[@CR4], [@CR15], [@CR16], [@CR18]--[@CR21]\].

In the 2014, at the American Society of Clinical Oncology (ASCO) annual meeting, both HER2 positivity and the Lauren classification were considered as the most important progresses in gastric cancer in the last 50 years. These were two important pathological features of gastric cancer. In the present study, we combined these two factors together and proposed the concept of L-H status. Since mixed type was not a pure group, L-H status is not a good option for mixed type. We only considered intestinal and diffuse type in the analysis. We divided the gastric cancer patients according to their L-H status to create four groups: Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; and Group D, HER2 positive and diffuse type. Group C had the largest number of patients. Unsurprisingly, the patients in Group A had the best prognosis, while those in Group D had the worst. Although both intestinal type and L-H status were independent prognostic factors in the multivariate analysis, the -2log likelihood was smaller in the L-H status model: the smaller the value of this statistic, the better the model. Therefore, the L-H status was better than the Lauren classification for predicting the prognosis.

In the multivariate analysis, age, TNM stage and L-H status were all independent prognostic factors for gastric adenocarcinoma patients. The L-H status could replenish the TNM stage. Moreover, we found that L-H status was an independent prognostic factor in stage I + II and stage III + IV patients. Although the L-H status was not useful in the mixed type, we recommend that all the gastric cancer patients should be subjected to Lauren classification and their HER2 status checked to determine their L-H status. It is not only helpful to evaluate prognosis, but also is helpful to decide treatment. For HER2 positive metastasis gastric cancer patients, trastuzumab is the standard treatment.

The limitations of the present study are: 1) its retrospective nature from a single-institution; 2) the fact that the impact of various treatment-related outcomes could not be fully evaluated; and 3) that progression free survival or disease free survival could not be fully analyzed.

External validation using other large databases or prospective studies to evaluate the prognostic effect of L-H status is required. The underlying mechanism of intestinal type gastric cancer and relationship with high HER2 expression requires further exploration.

Conclusions {#Sec18}
===========

In this large sample size study, we found that HER2 positivity was not an independent prognostic factor in the whole group of patients, but it was in the intestinal type and stage I and II patients. The combination of the Lauren classification and HER2 status (L-H status) was a better prognostic factor than the Lauren classification alone in the diffuse and intestinal type. We recommend that all the gastric cancer patients should be subjected to Lauren classification and their HER2 status checked to determine their L-H status.
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